Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Comparative evaluation of SARS-CoV-2 serological tests shows significant variability in performance across different years of infection and between the tests
Journal of Clinical Virology Plus, Volume 3, No. 4, Article 100168, Year 2023
Notification
URL copied to clipboard!
Description
Introduction: While the global COVID-19 pandemic is slowly coming under control, current efforts are focused on understanding the epidemiology of endemic SARS-CoV-2. The tool of choice for doing so remains serological tests that detect SARS-CoV-2 induced antibodies. However, the performance of these tests should be evaluated to ensure they comply with the specific performance criteria desired by each country that they are used in. Methods: Here, we use pre-COVID-19 plasma and plasma from SARS-CoV-2-infected individuals collected in 2020, 2021 and 2022 to evaluate the performance of two commercial Rapid Lateral Flow (RLF) tests (the PANBIO™ COVID-19 IgG/IgM rapid test and the LABNOVATION™ COVID-19 (SARS-CoV-2) IgG/IgM rapid test) and one commercial ELISA test (the PLATELIA™ SARS-CoV-2 total Ab). Results: We find that whereas the specificity of the two RLF tests is ≥ 95%, it was 91% for the ELISA tests. However, at 14 days post-COVID-19 date of diagnosis (DoD), only the ELISA test constantly achieved a sensitivity of ≥80% over all the three years. In addition, the rate of detection of the two RLF tests varied across the years with a sensitivity ranging from <80% in 2021 to >80% in 2022. More importantly the capacity of these two RLF tests to detect IgG antibodies decreased with time. On the contrary, the sensitivity of the ELISA test was still above 80% more than six months post DoD. Conclusion: We recommend that sero-epidemiological surveys focused on testing antibodies should not rely on performances reported by the assay manufacturers. They should include a formal evaluation of the selected assays to ensure its limitations and strengths conform with the data-accuracy requirements of the surveys. © 2023
Authors & Co-Authors
Nguefack-Tsague, Georges
Cameroon, Yaounde
Université de Yaoundé I
Penlap, Véronique B.
Cameroon, Yaounde
Université de Yaoundé I
Maïdadi, Martin Foudi
Cameroon, Yaounde
Institute of Medical Research and Medicinal Plant Studies Yaounde
Godwe, Célestin
Cameroon, Yaounde
Institute of Medical Research and Medicinal Plant Studies Yaounde
Njayou, Fréderic Nico
Cameroon, Yaounde
Université de Yaoundé I
Bigoga, Jude Daiga
Cameroon, Yaounde
Université de Yaoundé I
Ntoumi, Francine
Congo, Brazzaville
Fondation Congolaise Pour la Recherche Médicale Fcrm
Mpoudi-Ngolé, Eitel
Cameroon, Yaounde
Institute of Medical Research and Medicinal Plant Studies Yaounde
Tongo, Marcel
Cameroon, Yaounde
Institute of Medical Research and Medicinal Plant Studies Yaounde
Statistics
Authors: 9
Affiliations: 3
Identifiers
Doi:
10.1016/j.jcvp.2023.100168
ISSN:
26670380
Research Areas
Covid
Study Design
Cross Sectional Study